EXKIVITY
PeakNDAORALCAPSULEPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXKIVITY is an oral small-molecule capsule approved by the FDA on September 15, 2021, manufactured by Takeda. The specific indication, mechanism of action, and pharmacologic class are not available in the current dataset. As a newly approved NDA product, EXKIVITY represents a recent market entry in Takeda's portfolio.
$0.0BPart D
9.0 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EXKIVITY currently has zero linked job openings, suggesting either full organizational staffing or limited recruitment activity. Career opportunities would typically span brand management, medical science liaisons, field sales, and market access roles for a peak-stage product. Key skills would include indication-specific clinical knowledge, payer navigation, and early-commercialization experience, though specific role demand cannot be assessed with current data.
Company
Worked on EXKIVITY at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.